Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 69

recruiting
3 987
countries
28
conditions
2 109

988 trials match your criteria

Bladder cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Tremelimumab, and Chemotherapy in Patients with Advanced Bladder or Urinary System Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Anxiety disorder

Not recruiting

Long-Term Safety Study of Troriluzole for Patients with Obsessive Compulsive Disorder Not Responding to SSRI, Clomipramine, Venlafaxine, or Desvenlafaxine

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Troriluzole

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Charcoal, Activated

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib

Pseudomonas infection

Not recruiting

Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone to Bortezomib with Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Study of CLR 131 for Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Iopofosine (131I)

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ocrelizumab

Study on the Safety and Efficacy of Linsitinib for Patients with Active, Moderate to Severe Thyroid Eye Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Linsitinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.